Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | GFER | P55789 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | NOS1 | P29475 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | HBB | P68871 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1006897 | 1.00 | ALDH1A1 (0.55) | ALDH1A1HPGDGFERALOX15HSD17B10 | |
| SCHEMBL21215222 | 0.81 | KDM1A (0.60) | ALDH1A1HPGDGFERALOX15HSD17B10 | |
| SCHEMBL5579647 | 0.77 | ALDH1A1 (0.84) | ALDH1A1HPGDGFERALOX15HSD17B10 | |
| SCHEMBL102214 | 0.75 | CYP2D6 (0.55) | ALDH1A1GFERALOX15HSD17B10GAA | |
| SCHEMBL10173256 | 0.75 | CYP2D6 (0.55) | ALDH1A1GFERALOX15HSD17B10GAA | |
| SCHEMBL102213 | 0.75 | CYP2D6 (0.55) | ALDH1A1GFERALOX15HSD17B10GAA | |
| SCHEMBL12573230 | 0.74 | ALDH1A1 (0.55) | ALDH1A1HPGDGFERALOX15HSD17B10 | |
| SCHEMBL10092621 | 0.74 | KDM1A (0.54) | ALDH1A1HPGDGFERALOX15HSD17B10 | |
| SCHEMBL21215275 | 0.73 | RAB9A (0.48) | ALDH1A1HPGDGFERALOX15HSD17B10 | |
| SCHEMBL4051722 | 0.73 | ALDH1A1 (0.55) | ALDH1A1HPGDALOX15HSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114775002-A | Environment-friendly electroplating solution for wafer packaging and preparation method thereof | 江苏矽智半导体科技有限公司 | 2022-07-22 | — | — | CN | claimed |
| CN-114775002-A | Environment-friendly electroplating solution for wafer packaging and preparation method thereof | 江苏矽智半导体科技有限公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-114775002-A | Environment-friendly electroplating solution for wafer packaging and preparation method thereof | 江苏矽智半导体科技有限公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-106366078-A | Indazole-oxadiazole derivative, medicinal composition containing derivative, and application of derivative in tumor prevention | 浙江大学 | 2017-02-01 | — | — | CN | disclosed |
| EP-2970262-A1 | BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9050346-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2015-06-09 | — | — | US | disclosed |
| WO-2014164771-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20140256705-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. | 2014-09-11 | — | — | US | disclosed |
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-19 | — | — | US | disclosed |
| EP-2269990-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-7435750-B2 | Method of using substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7041685-B2 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| US-20050154012-A1 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2005-07-14 | — | — | US | disclosed |
| CN-1638776-A | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs | CYTOVIA INC (US) | 2005-07-13 | — | — | CN | disclosed |
| EP-1406632-A2 | SUBSTITUTED 3-ARYL-5-ARYL- 1,2,4]-OXADIAZOLES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20030045546-A1 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-03-06 | — | — | US | disclosed |
| WO-2002100826-A2 | SUBSTITUTED 3-ARYL-5-ARYL-[1,2,4]-OXADIAZOLES AND ANALOGS | CYTOVIA, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045546-A1 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP3, CASP1, API5 | ALDH1A1 136/4885HPGD 1435/4885GFER 2381/4885 |
| US-20140256705-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | ALDH1A1 1453/4885HPGD 1411/4885GFER 4601/4885 |
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | GRIN1, GRM1, GRIK1 | ALDH1A1 614/4885HPGD 2564/4885GFER 1046/4885 |
| US-20050154012-A1 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP3, CASP1, CASP4 | ALDH1A1 229/4885HPGD 1834/4885GFER 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.